Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2007;50(1):16-23.

PMID:
17164553
2.

Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.

Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2012 Aug;84(8):1199-207. doi: 10.1002/jmv.23288.

PMID:
22711347
3.
4.

A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.

Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J.

J Infect Chemother. 2003 Dec;9(4):333-40.

PMID:
14691655
5.

Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.

Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2004;47(6):355-61.

PMID:
15564748
7.

Long-term cohort study of chronic hepatitis C according to interferon efficacy.

Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.

J Gastroenterol Hepatol. 2012 Feb;27(2):291-9. doi: 10.1111/j.1440-1746.2011.06871.x.

PMID:
21793911
8.

Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.

J Gastroenterol Hepatol. 2005 May;20(5):752-8.

PMID:
15853990
9.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
10.
11.

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

Giannini EG, Basso M, Savarino V, Picciotto A.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):502-8. doi: 10.1111/j.1365-2036.2009.04201.x. Epub 2009 Nov 19.

12.

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S.

Liver Int. 2007 Mar;27(2):186-91.

PMID:
17311612
13.

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

Int J Cancer. 2000 Sep 1;87(5):741-9.

14.

Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center.

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H.

Intervirology. 2006;49(1-2):82-90.

PMID:
16166794
15.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052
17.

Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.

Ann Intern Med. 2007 May 1;146(9):649-56.

PMID:
17470833
18.

The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.

Dohmen K, Kawano A, Takahashi K, Shigematsu H, Tanaka H, Haruno M, Yanagita K, Ichiki Y, Mori T, Hayashida K, Shimoda S, Ishibashi H, Nomura H.

Hepatogastroenterology. 2013 Nov-Dec;60(128):2034-8.

PMID:
24719946
19.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
20.

The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y.

Cancer. 2000 Jan 1;88(1):58-65.

PMID:
10618606

Supplemental Content

Support Center